If you think the broader market’s extreme pendulum swings are the definition of volatility, you should have a conversation with long–term investors of vaccine specialist Novavax (NVAX). To quickly recap the last 24 …
As record levels of volatility continue to plague the market, investors globally have been left grappling with the economic fallout. After landing in …
For better or for worse (but mostly for better), COVID-19 has taken Novavax (NVAX) on a very wild ride. Since the first report …
Coronavirus fears have weighed heavily on the market, and investors are seeking refuge. While the situation in China is reportedly improving, health officials …
Fears that China’s outbreak of a new “coronavirus” shocked the stock market on Monday, sending the S&P 500 down 1.57% — and slicing …
When investment bank Oppenheimer talks, investors listen — or they should. One of the 10 top performing research firms tracked by TipRanks, 61% …
After a massive slip up last year, the tide appears to be turning for small cap vaccine maker Novavax (NVAX). In Wednesday’s trading …
For the uninitiated, biotech stocks can seem a tad intimidating. The untrained eye is confronted with masses of obscure data, clinical trial information …
Novavax (NVAX) shareholders have had a rough 2019, to say the least, as Mr. Market chopped off more than 90% of the company’s …
2019 has been a good year for the stock market. Year-to-date, both the S&P 500 and the Nasdaq are up 15% and 19%, …
